Correlation between anti-müllerian hormone in polycystic ovarian syndrome with metformin: a systematic review and meta-analysis

References

• Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet. Diabetes Endocrinol. 2022;10(9):668–680. doi:10.1016/S2213-8587(22)00163-2.
   PubMed Web of Science ®Google Scholar
• Goodman NF, Cobin RH, Futterweit W, et al. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome–part 1. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2015;21(11):1291–1300.
   Google Scholar
• Harborne L, Fleming R, Lyall H, et al. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet. 2003;361(9372):1894–1901. doi: 10.1016/S0140-6736(03)13493-9.
   PubMed Web of Science ®Google Scholar
• Laura P, Laurine H, Mark B, et al. Granulosa cell production of anti-müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007;92(1):240–245. doi:10.1210/jc.2006-1582.
   PubMed Web of Science ®Google Scholar
• van Rooij JAI, Broekmans MJF, te Velde, ER, et al. Serum anti-müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod (Oxford, England). 2002;17(12):3065–3071. doi:10.1093/humrep/17.12.3065.
   PubMed Web of Science ®Google Scholar
• Webber L, Stubbs S, Stark J, et al. Formation and early development of follicles in the polycystic ovary. Lancet. 2003;362(9389):1017–1021. doi: 10.1016/s0140-6736(03)14410-8.
   PubMed Web of Science ®Google Scholar
• Carlsen SM, Vanky E, Fleming R. Anti-Mullerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod. 2009;24(7):1732–1738. doi:10.1093/humrep/dep074.
   PubMed Web of Science ®Google Scholar
• Piltonen TT, Komsi E, Morin-Papunen LC, et al. AMH as part of the diagnostic PCOS workup in large epidemiological studies. Euro J Endocrinol. 2023;188(6):547–554. doi:10.1093/ejendo/lvad065.
   Web of Science ®Google Scholar
• Wei WY, Chang CH, Ru YC, et al. The effect of medication on serum anti-müllerian hormone (AMH) levels in women of reproductive age: a meta-analysis. BMC Endocr Disord. 2022;22(1):158. doi:10.1186/s12902-022-01065-9.
   Web of Science ®Google Scholar
• Rethlefsen ML, Kirtley S, Waffenschmidt S, et al. PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. J Med Lib Assoc JMLA. 2021;109(2):174–200. doi:10.5195/jmla.2021.962.
   PubMed Web of Science ®Google Scholar
• Claudio L, Nicola V, Alessia N, et al. Assessing the quality of studies in meta-research: review/guidelines on the most important quality assessment tools. Pharm Stat. 2020;20(1):185–195. doi:10.1002/pst.2068.
   PubMed Web of Science ®Google Scholar
• Yumiko T, Yoshikazu K, Yuko H, et al. Anti-müllerian hormone levels in the diagnosis of adolescent polycystic ovarian syndrome: a systematic review and meta-analysis. Endocrine Journal. 2022;69(8):897–906. doi:10.1507/endocrj.EJ22-0081.
   PubMed Web of Science ®Google Scholar
• Hughes L, Komorowski AS, Aaby DA, et al. The effect of clomiphene, metformin, or both on anti- müllerian hormone (amh) levels: a new look at the pregnancy in polycystic ovarian syndrome trial (ppcos I). Fertil Steril. 2022;118(4S):e193–e193, doi:10.1016/j.fertnstert.2022.08.549.
   PubMedGoogle Scholar
• Fatemeh F, Mansooreh S, Hosseini KA, et al. Effect of metformin on the anti-müllerian hormone level in infertile women with polycystic ovarian syndrome. Electron Phys. 2017;9(12):5969–5973. doi:10.19082/5969.
   Google Scholar
• Panidis D, Georgopoulos NA, Piouka A, et al. The impact of oral contraceptives and metformin on anti-müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2011;27(8):587–592. doi:10.3109/09513590.2010.507283.
   PubMed Web of Science ®Google Scholar
• Romualdi D, De Cicco S, Tagliaferri V, et al. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011;96(5):E821–E824. doi:10.1210/jc.2010-1725.
   PubMed Web of Science ®Google Scholar
• Carlsen SM, Vanky E, Fleming R. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod. 2009;24(7):1732–1738. doi: 10.1093/humrep/dep074.
   PubMed Web of Science ®Google Scholar
• Aykut B, Heather T, Rebecca U, et al. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fert Steril. 2007;87(4):870–875. doi: 10.1016/j.fertnstert.2006.08.096.
   PubMed Web of Science ®Google Scholar
• Nazirudeen R, Sridhar S, Priyanka R, et al. A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2023;99(2):198–205. doi: 10.1111/cen.14931.
   PubMed Web of Science ®Google Scholar
• Delbar D, Soleimani MM, Shahrzad Z, et al. Sitagliptin/metformin improves the fertilization rate and embryo quality in polycystic ovary syndrome patients through increasing the expression of GDF9 and BMP15: a new alternative to metformin (a randomized trial.). J Reprod Immunol. 2022;150(prepublish):103499.
   PubMedGoogle Scholar
• Keerthana R, Neena M, Reeta M, et al. Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2021;38(2):1–8.
   Web of Science ®Google Scholar
• Chhabra N, Malik S. Effect of insulin sensitizers on raised serum anti-mullerian hormone levels in infertile women with polycystic ovarian syndrome. J Hum Reprod Sci. 2018;11(4):348–352. doi: 10.4103/jhrs.JHRS_59_17.
   PubMedGoogle Scholar
• Diogo AN, Alves LLS, Carolina ARSDJ, et al. Effects of metformin on serum insulin and anti-mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2013;29(3):246–249. doi:10.3109/09513590.2012.736563.
   PubMed Web of Science ®Google Scholar
• Wiweko B, Susanto AC. The effect of metformin and cinnamon on serum anti-mullerian hormone in women having PCOS: a Double-Blind, randomized, controlled trial. J Hum Reprod Sci. 2017;10(1):31–36. doi:10.4103/jhrs.JHRS_90_16.
   PubMedGoogle Scholar
• Neagu M, Cristescu C. Anti-Műllerian hormone–a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome. J Med Life. 2012;5(4):462–464.
   PubMedGoogle Scholar
• Angela F, Morena R, Tiziana R, et al. Serum and follicular anti-mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin. J Ovarian Res. 2010;3(1):16. doi:10.1186/1757-2215-3-16.
   Google Scholar
• Terhi P, Laure M, Riitta K, et al. Serum anti-müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod (Oxford, England). 2005;20(7):1820–1826. doi:10.1093/humrep/deh850.
   PubMed Web of Science ®Google Scholar
• Francisco F, Camil C, Francisco C, et al. The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive age. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2011;27(4):216–224. doi:10.3109/09513590.2010.487595.
   PubMed Web of Science ®Google Scholar
• Tomova A, Deepinder F, Robeva R, et al. Anti-Mullerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. Horm Metab Res. 2011;43(10):723–727. doi:10.1055/s-0031-1286307.
   PubMed Web of Science ®Google Scholar
• Madsen HN, Lauszus FF, Trolle B, et al. Impact of metformin on anti-müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial. Acta Obstet Gynecol Scand. 2015;94(5):547–551. doi: 10.1111/aogs.12605.
   PubMed Web of Science ®Google Scholar
• Saleh BO, Ibraheem WF, Ameen NS. The role of anti-Mullerian hormone and inhibin B in the assessment of metformin therapy in women with polycystic ovarian syndrome. Saudi Med J. 2015;36(5):562–567. doi: 10.15537/smj.2015.5.11112.
   PubMed Web of Science ®Google Scholar
• Froment P, Plotton I, Giulivi C, et al. At the crossroads of fertility and metabolism: the importance of AMPK-dependent signaling in female infertility associated with hyperandrogenism. Hum Reprod. 2022;37(6):1207–1228. doi: 10.1093/humrep/deac067.
   PubMed Web of Science ®Google Scholar
• Harborne LR, Sattar N, Norman JE, et al. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005;90(8):4593–4598. doi:10.1210/jc.2004-2283.
   PubMed Web of Science ®Google Scholar
• Fleming R, Harborne L, MacLaughlin DT, et al. Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fert Steril. 2005;83(1):130–136. doi:10.1016/j.fertnstert.2004.05.098.
   PubMed Web of Science ®Google Scholar
• Zhijiao Z, Hongzhi C, Ling C, et al. The effects of metformin on anti-müllerian hormone levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis. J Ovarian Res. 2023;16(1):123. doi: 10.1186/s13048-023-01195-1.
   PubMed Web of Science ®Google Scholar
• Moolhuijsen LME, Visser JA. Anti-müllerian hormone and ovarian reserve: update on assessing ovarian function. J Clin Endocrinol Metab. 2020;105(11):3361–3373. doi: 10.1210/clinem/dgaa513.
   PubMed Web of Science ®Google Scholar
• Tunc HT, Dilek C, Ozlem DG, et al. Determining the age group-based cut-off values of serum anti-mullerian hormone concentrations to diagnose polycystic ovary syndrome. Curr Med Res Opin. 2023;39(6):855–863. doi:10.1080/03007995.2023.2204768.
   Web of Science ®Google Scholar